ProSciento Closes Growth Financing from 1315 Capital Read More »
ProSciento Appoints Stephen Mullennix as Chief Financial Officer Read More »
View Recent Webinar
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients. Read More »
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials. Read More »
ProSciento’s State-of-the-Art Clinical Research Center for Metabolic Studies Read More »
